Abstract:Objective To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer.Methods One hundred and ninety-two cases of metastatic hormone-sensitive prostate cancer in Renji Hospital between January 2015 and July 2016 were analyzed retrospectively.Patients' age was 39 to 90,the median age was 71 years.The median prostate-specific antigen (PSA) at diagnosis was 90.6ng/ml (4.1-2 556.0 ng/ml).One hundred and eighty were with bone metastasis and 12 were with distant lymphatic metastasis.Sixty-one of them received docetaxel chemotherapy plus ADT for 3 weeks,131 received hormonal treatment alone.The median age of combination therapy group was 67 years (39-80 years),that of single treatment group was 75 years (50-93 years) (P ＜ 0.001).The median PSA baseline of the two groups were 91.6 ng/ml (35.5-157.5ng/ml) and 89.1 ng/ml (59.6-191.0 ng/ml) (P =0.324).Gleason score of combination therapy group showed that 3 cases (4.9％) was 6,23 cases (37.7％) 7,35 cases (57.4％) ≥8.That of single treatment group showed that 17 cases (13.0％) 6,51 cases (38.9％) 7,63 cases (48.1％) ≥8.There was no statistic difference between the two groups (P =0.122).But there was statistic difference in the rate of T3 or T4 clinical stage in primary lesion,that of combination therapy group was 50.7％ (37/61) and 34.4％ (21/61),and that of single treatment group was 60.3％ (79/131) and 21.4％ (28/131) (P =0.011).Imaging showed local lymph node metastasis in the two groups (80.3％ vs.67.9％,P =0.005).As to physical condition,the combination therapy group showed a lower ECOG score than the single treatment group (P ＜ 0.001).All the patients' survival condition,PSA response rate and adverse events were analyzed.Results One hundred and ninety-two patients were regularly followedup.The median follow-up time was 23.3 (14.4-33.4) months.Median progression free survival time of combination therapy group and single treatment group were respectively 24.4 (7.5-31.3) months vs.17.5(3.0-30.7) months (P ＜ 0.001).There were 1 and 16 cases died in the two groups due to disease progression.During the treatment,the rate of PSA level less than 0.2 ng/ml was 29.5％ (18/61) vs.13.7％ (18/131) in combination therapy group and single treatment group.Regarding the tolerance of combination therapy group,the incidence rate of grade 3-4 neutropenia was 27.9％ (17/61).Skin and mucous membrane damaged in 24.6％ (15/61) patients,transaminase rised in 13.1％ (8/61) patients,and peripheral nerve toxicity occurred in 9.8％ (6/61) patients.There was no significant difference between the 2 groups in relevant events caused by ADT,gynecomastia (14.8％ vs.16.3％) and erectile dysfunction (100％ vs.100％).Most of them could be relieved by symptomatic treatment.Conclusions For metastatic hormone-sensitive prostate cancer,docetaxel combined with hormonal treatment showed longer progression free survival than ADT alone with adverse reactions acceptable.

Analysis of Hormonal Therapy for Advanced Metastatic Prostate Cancer

667 THE ANALYSIS OF THE EFFECT OF HORMONAL THERAPY FOR ADVANCED METASTATIC PROSTATE CANCER IN CHINESE PATIENTS

[The Survival Analysis of Metastatic Prostate Cancer].

[The Survival Analysis of the Advanced Metastatic Castration-Resistant Prostate Cancer].

Prognostic factors of progression to hormone-refractory stage after hormone therapy for prostate cancer

[Epidemiology of Prostate Cancer from Three Centers and Analysis of the First-Line Hormonal Therapy for the Advanced Disease].

Clinical Analysis on the Treatment of Prostate Cancer

Analysis of Clinical Factors Impacting on the Effective Time of Endocrine Therapy for Patients with Prostate Cancer

Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents

Clinical Analysis of Prostate Cancer with Bone Metastasis: A Report of 63 Cases

[Factors Influencing the Progression-Free Survival Time of Prostate Cancer Patients after Endocrine Therapy].

Adjuvant Hormone Therapy after Radical Prostatectomy in High-Risk Localized and Locally Advanced Prostate Cancer: First Multicenter, Observational Study in China

Analysis of Prognostic Factors Associated with Survival in Men with Prostate Cancer Accompanied by Spinal Metastases at First Diagnosis

Prognosic Analysis of Chemotherapy for Patients with Castration Resistant Prostate Cancer

Local treatment for the prognosis of hormone-sensitive metastatic prostate cancer: a Meta-analysis

Evaluation of Endocrine Therapy Combined with Intensity Modulated Radiation Therapy in Patients with Advanced Prostate Cancer

The clinical analysis on endocrine therapy of late prostate carcinoma

The effects of clinical characteristics on the numbers of metastasis positions in prostate cancer patients

Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer

Clinical features and prognostic factors for patients with bone metastases from prostate cancer.

Docetaxel Chemotherapy Combined with Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: an Efficacy and Safety Analysis